Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug... see more

Bullboard (NDAQ:SCYX)

View:
Prev 1 2 3
User Avatar Image
(17)
•••
  • gisellekronkX
Post by gisellekronkon Feb 19, 2020 1:19pm

up ten cents

woo hoo , the start of something or just more dissapointment ? 
71
Post by Tcheckon Jan 08, 2020 12:46pm

good news

sadly it is used only to recover lost ground .
60
User Avatar Image
(17)
•••
  • gisellekronkX
Post by gisellekronkon Dec 23, 2019 6:53am

they like us

Hedge Fund Armistice Capital Reports 5.7% Stake in Scynexis
84
User Avatar Image
(17)
•••
  • gisellekronkX
Post by gisellekronkon Dec 10, 2019 11:54am

down

SCYNEXIS Prices $35 Million Offering of Common Stock, Warrants ..  this stock is no different from holding junior gold miners . unless they strick it big , you wont make any money . 
68
Post by Tcheckon Nov 04, 2019 10:01am

finally

selling pressure is off
48
Post by Tcheckon Aug 17, 2019 9:14am

Scyx against superbug

The drug-resistant fungus, Candida auris, was only discovered 10 years ago, but is now one of the world's most feared hospital microbes. These infections are usually quite serious. Around ...more  
148
User Avatar Image
(17)
•••
  • gisellekronkX
Comment by gisellekronkon Aug 08, 2019 11:34am

RE:cure worse than the disease

``they should invent a product to kill off the molds attracking this stock `` , good one , lol
60
Post by Tcheckon Aug 02, 2019 2:03pm

cure worse than the disease

instead of treating fungi they should invent a product to kill off the molds attracking this stock . hedgefunds and all other parasites feasting on companies weaknesses . do thay have a miracle ...more  
105
Post by Tcheckon May 22, 2019 11:54am

going to the dogs

it was not to be
52
Post by Tcheckon May 01, 2019 10:12am

a company worth supporting

May 1 (Reuters) - SCYNEXIS Inc : * SCYNEXIS TO PRESENT DATA AT ACOG 2019 FURTHER DEMONSTRATING THE FAVORABLE PROFILE OF IBREXAFUNGERP FOR THE TREATMENT OF VULVOVAGINAL CANDIDIASIS (VVC)
65
Prev 1 2 3
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >